Navigation Links
Aviir, Inc.'s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Women's Expo

IRVINE, Calif., Nov. 4, 2012 /PRNewswire/ -- Dr. Douglas Harrington, CEO of Aviir, Inc., joined a host of influential companies and experts at the Los Angeles Ultimate Women's Expo on Saturday, October 27 to discuss America's leading threat to women: Heart Disease. Dr. Harrington's lecture "Everything You Ever Wanted to Know About Heart Disease But Were Afraid to Ask" provided a higher level of insight into the disease and how women can empower themselves, improving their cardiovascular health.  The speaking session began at 12:30 PM, at the Los Angeles Convention Center and was sponsored by GuardaHeart Foundation.

(Photo: )

As CEO of Aviir, Inc., Dr. Harrington brings more than 25 years of experience in the commercialization of health care technology. Aviir, Inc. is an Irvine-based biotechnology company that develops innovative diagnostic and laboratory tests. Dr. Harrington's personal mission is to offer clarity to heart disease through reliable assessments and prevention.

The Los Angeles Ultimate Women's Expo sought out some of the best seminar speakers around the world to participate in their event, which is held in several cities across the country.

GuardaHeart sponsors heart risk assessments through an on-going collaboration with Aviir.  Far too many lives continue to be needlessly lost to heart disease, while many more are burdened with the medical debt caused by surviving a heart attack.

"Heart Disease remains the leading cause of death in the US, claiming almost 600,000 lives each year, yet many are unaware that 80% of heart disease is preventable through lifestyle modification," said Dr. Harrington.  Through GuardaHeart's movement "Pledge to SaveThe1" individuals are empowered and equipped to make these critical lifestyle modifications.

Dr. Harrington also discussed an innovative blood test, developed through an Aviir/Stanford University cardiology collaboration, which identifies an individuals' cardiac risk in a five-year timeframe.  "This timeframe allows preventive measures to be implemented," continued Dr. Harrington. "Our mission is to improve healthcare and encourage timely preventive strategies by providing this unique medical information."

About Aviir, Inc.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.  Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit for more information.

About Los Angeles Ultimate Women's Expo
The Ultimate Women's Expo unites thousands of women with the most respected companies and brands that provide valuable products and services designed to enrich the lives of women. Indulge with the very best Los Angeles has to offer in shopping, fashion, food, entertainment, cosmetics, health and wellness and travel. Expo hours are October 27 and 28 from 10:00 AM. For more information, visit:

For media inquiries, please contact: Dina Scaglione (949) 398-6320

For Interviews at the Expo please contact:
Yvette Morales
YM & Associates
PR | Marketing | Branding | Business Development
California | New York
949.244.9769 | 310.499.0906 Fax
Twitter: @YMTheBevHillsPR

SOURCE Aviir, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
2. Uncertainty Surrounding How to Optimize Laboratory Services?
3. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
4. Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia
5. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
6. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
7. First Baby With Artificial Heart in Japan
8. Mending a broken heart -- with a molecule that turns stem cells into heart cells
9. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
10. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
11. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... ... , ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, ... serve as Chief Operating Officer. , Having joined InSphero in November 2013 ... was promoted to Head of InSphero Diagnostics in 2014. There she has built ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced broader entry into the automotive market ... that match the pace of consumer electronics human interface ... sensors are ideal for the automotive industry and will ... Europe , Japan ...
(Date:10/29/2015)... MINNETONKA, Minn. , Oct. 29, 2015   ... that supports the entire spectrum of clinical research, is ... the Minnesota High Tech Association (MHTA) as one of ... in the "Software – Small and Growing" category. The ... and individuals who have shown superior technology innovation and ...
Breaking Biology News(10 mins):